Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index (DLQI) as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol. 2012 Jan;132(1):76-84. doi: 10.1038/jid.2011.238

The Dermatology Life Quality Index (DLQI) is a widely used health-related quality of life measure. However, little research has been conducted on its dimensionality. The objectives of the current study were to apply Rasch analysis toDLQIdata to determine whether the scale is unidimensional, to assess its measurement properties, test the response format, and determine whether the measure exhibits differential item functioning (DIF) by disease (atopic dermatitis versus psoriasis), gender, or age group. The results show that there were several problems with the scale, including misfitting items, DIF by disease, age, and gender, disordered response thresholds, and inadequate measurement of patients with mild illness. As theDLQIdid not benefit from the application of Rasch analysis in its development, it is argued that a new measure of disability related to dermatological disease is required. Such a measure should use a coherent measurement model and ensure that items are relevant to all potential respondents. The current use of theDLQIas a guide to treatment selection is of concern, given its inadequate measurement properties.Comment inDermatology life quality index: time to move forward.[J Invest Dermatol. 2012]

Share on: